(VIANEWS) - Genmab (GMAB), UMH Properties (UMH), Universal Health Services (UHS) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Genmab (GMAB)
31.8% sales growth and 17.71% return on equity
Genmab A/S is a Danish company that develops and markets antibody therapies for cancer treatment. DARZALEX is a monoclonal human antibody that can be used to treat multiple myeloma. Teprotumumumab is for treatment of thyroid disease. Ofatumurnab (a human monoclonal anti-body for chronic lymphocyticleukemia (CLL), multiple sclerosis) and Amivantamab (for advanced, metastatic, or esophageal, cancers and NSCLC) are also available. Daratumumab is used to treat MM and non-MM blood tumors and AL Amyloidosis. It also produces products. Phase 2 includes Teclistamab to treat vaso-occlusive crisis; Camidanlumab tesirine for treatment of hodgkin lymphoma; JNJ-64407564 for treating MM; and PRV-015 to treat celiac disorder. It also has 20 preclinical trials. Seagen Inc. has granted the company a collaboration and commercial license to develop tisotumab. The company also has a partnership agreement with CureVac AG to research and develop differentiated mRNA-based antibodies products. AbbVie is responsible for developing epcoritamab. There are collaborations with BioNTech, Janssen, Novo Nordisk A/S, Bolt Biotherapeutics, Inc. Genmab A/S was established in 1999. Its headquarters are in Copenhagen, Denmark.
Earnings Per Share
As for profitability, Genmab has a trailing twelve months EPS of $0.66.
PE Ratio
Genmab has a trailing twelve months price to earnings ratio of 68.85. Meaning, the purchaser of the share is investing $68.85 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 17.71%.Annual Top and Bottom Value
Genmab stock was valued at $45.52 as of 15:22 EST. This is below the 52-week high at $47.50, and much higher than its 52 week low at $26.19.
Moving Average
Genmab is worth more than its $50.30 moving average and much higher than its $35.47 moving average over 200 days.Growth Estimates Quarters
For the next quarter, the company expects to grow by 492.6% and 1252.9% respectively.Revenue growth
The year-on-year revenue growth was 60.3%. It now stands at 10.21B in the 12 trailing months.
2. UMH Properties (UMH)
10.6% sales growth and 3.03% return on equity
UMH Properties, Inc., which was organized in 1968, is a public equity REIT that owns and operates 124 manufactured home communities containing approximately 23,400 developed homesites. These communities are located in New Jersey, New York, Ohio, Pennsylvania, Tennessee, Indiana, Michigan and Maryland. In addition, the Company owns a portfolio of REIT securities.
Earnings per Share
UMH Properties' trailing 12 month EPS is $-0.72.
For the 12 trailing months, the company's return-on-equity, which is a measure of the profitability and shareholder equity for a company, was 3.03%.3. Universal Health Services (UHS)
6.9% sales growth and 11.73% return on equity
Universal Health Services, Inc., via its subsidiaries, operates outpatient and behavioral healthcare facilities, as well as acute care hospitals. Acute Care Hospital Services, and Behavioral Health Care Services are the two segments that make up Universal Health Services Inc. The hospitals provide general and specialty surgery as well as internal and pediatric medicine. It owned or operated 360 outpatient facilities, 39 outpatient, and other facilities in 38 US states, Washington, D.C., the United Kingdom, Puerto Rico, and Puerto Rico. It also offers commercial insurance services. Universal Health Services, Inc. was founded in 1978. It is located in King of Prussia, Pennsylvania.
Earnings Per Share
As for profitability, Universal Health Services has a trailing twelve months EPS of $11.79.
PE Ratio
Universal Health Services has a trailing twelve months price to earnings ratio of 10.99. Meaning, the purchaser of the share is investing $10.99 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 11.73%.Growth Estimates Quarters
For the current quarter, the company expects to grow by 3.4% and 19.1% respectively.Sales Growth
Universal Health Services saw a 3.8% increase in sales for the current quarter, and 6.9% the following.
Revenue Growth
Year-on-year quarterly revenue growth grew by 5.7%, now sitting on 13.23B for the twelve trailing months.
4. West Pharmaceutical (WST)
5.8% sales growth and 30.76% return on equity
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Earnings per Share
West Pharmaceutical's trailing 12 month EPS is $5.57.
PE Ratio
West Pharmaceutical's trailing 12 months earnings to price ratio is 42.96. The purchaser of the shares is therefore investing $42.96 per dollar in annual earnings.
For the 12 trailing months, the company's return-on-equity, which is a measure of the profitability and shareholder equity for a business, was 30.76%.Volume
The West Pharmaceutical's current reported volume is 501490, which is 32.2% lower than its average volume at 739868.
Revenue growth
The year-on-year revenue growth was 6.6%. We now have 2.93 billion in the 12 trailing months.